Retour

Kissei Pharmaceutical Co., Ltd.

Qualité des données : 100%

Survendu

KSPHF

OTC Healthcare Drug Manufacturers - Specialty & Generic

25,77 €

0,00 € (0,00%)

Cap. Boursière : 1,07B

Fourchette du Jour

25,77 € 30,28 €

Fourchette 52 Semaines

23,23 € 31,90 €

Volume

100

Moyenne 50J / 200J

26,83 € / 27,79 €

Clôture Précédente

25,77 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique	Action	Médiane du Secteur
P/E	0,1	0,3
P/B	0,0	2,9
ROE %	5,6	3,7
Net Margin %	13,5	3,8
Rev Growth 5Y %	6,4	10,0
D/E	0,0	0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	318,00 € 291,47 € – 335,78 €	110 B	1
FY2029	309,94 € 284,08 € – 327,27 €	110 B	1
FY2028	339,24 € 310,94 € – 358,21 €	100 B	1

Points Clés

Revenue grew 6,35% annually over 5 years — modest growth

Debt/Equity of 0,01 — conservative balance sheet

Generating 1,49B in free cash flow

P/E of 0,09 — trading at a low valuation

Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,52%

Capital efficient — spends only 5,69% of revenue on capex

Croissance

Revenue Growth (5Y)

6,35%

Revenue (1Y)16,87%

Earnings (1Y)7,18%

FCF Growth (3Y)N/A

Qualité

Return on Equity

5,58%

ROIC2,06%

Net Margin13,54%

Op. Margin6,54%

Sécurité

Debt / Equity

0,01

Current Ratio6,45

Interest Coverage274,90

Valorisation

P/E Ratio

0,09

P/B Ratio0,01

EV/EBITDA-3,95

Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	16,87%	Revenue Growth (3Y)	14,40%
Earnings Growth (1Y)	7,18%	Earnings Growth (3Y)	6,59%
Revenue Growth (5Y)	6,35%	Earnings Growth (5Y)	22,65%
Profitability
Revenue (TTM)	88,33B	Net Income (TTM)	11,96B
ROE	5,58%	ROA	4,90%
Gross Margin	49,89%	Operating Margin	6,54%
Net Margin	13,54%	Free Cash Flow (TTM)	1,49B
ROIC	2,06%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,01	Current Ratio	6,45
Interest Coverage	274,90	Dividend Yield	0,02%
Valuation
P/E Ratio	0,09	P/B Ratio	0,01
P/S Ratio	0,01	PEG Ratio	1,16
EV/EBITDA	-3,95	Dividend Yield	0,02%
Market Cap	1,07B	Enterprise Value	-22,82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	88,33B	75,58B	67,49B	65,38B	69,04B
Net Income	11,96B	11,16B	10,53B	12,92B	5,29B
EPS (Diluted)	274,21	246,58	228,31	280,20	113,25
Gross Profit	44,07B	37,34B	223,56M	238,41M	279,53M
Operating Income	5,77B	4,02B	-1,13B	-1,40B	1,51B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	244,06B	260,93B	1,66B	1,96B	2,43B
Total Liabilities	33,93B	39,80B	198,58M	297,46M	442,57M
Shareholders' Equity	209,00B	220,03B	193,90B	201,38B	219,31B
Total Debt	1,28B	1,34B	1,49B	1,64B	1,74B
Cash & Equivalents	25,17B	22,89B	367,95M	246,56M	393,19M
Current Assets	106,98B	104,55B	100,64B	99,34B	92,97B
Current Liabilities	16,58B	17,66B	14,96B	18,74B	18,25B

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Deep Value Investing (Seth Klarman)

#783 of 827

Growth Price/Sales Ratio Focus (Ken Fisher)

#463 of 618

Value Defensive Investing (Benjamin Graham)

#666 of 709

Activité Récente

Entré Deep Value Investing (Seth Klarman)

Mar 24, 2026

Entré Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Entré Defensive Investing (Benjamin Graham)

Mar 24, 2026